Evidence map›Paper›PMID 42816478›Full record

ArticleBlood cancer journal2026

Real-world treatment patterns and outcomes of brentuximab vedotin-based therapy in CD30-positive lymphomas in China: the prospective BRAVE study.

Ming-Ci Cai, Ou Bai, Hui-Lai Zhang, Chuan-Xu Liu, Wen-Yang Huang, Li-Hong Liu, Zeng-Jun Li, Lu-Qun Wang, Li-Ping Su, Wei Zhang and 24 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Ming-Ci Cai *Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ou Bai *Department of Hematology, The First Hospital of Jilin University, Changchun, China.
Hui-Lai Zhang *Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.ORCID http://orcid.org/0000-0002-8558-3131
Chuan-Xu Liu *Department of Lymphoma and Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0002-3125-9547
Wen-Yang HuangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Li-Hong LiuDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Hebei Tumor Hospital, Shijiazhuang, China.
Zeng-Jun LiDepartment of Hematology, Shandong Cancer Hospital and Institute, Jinan, China.
Lu-Qun WangDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Li-Ping SuDepartment of Hematology, Shanxi Cancer Hospital, Taiyuan, China.
Wei ZhangDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID http://orcid.org/0000-0001-9489-5965
Wei XuDepartment of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Kai-Yang DingDivision of Life Sciences and Medicine, Department of Hematology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Guo-Hui CuiDepartment of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hong-Mei JingDepartment of Hematology, Peking University Third Hospital, Beijing, China.
Hua-Qing WangDepartment of Oncology, Tianjin Union Medical Center, Tianjin, China.
Zheng GeDepartment of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing, China.ORCID http://orcid.org/0000-0001-8028-1612
Fang ZhuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID http://orcid.org/0000-0002-2909-3736
Fei LiDepartment of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Xiao-Bo WangDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.ORCID http://orcid.org/0000-0001-5057-5919
Shen-Miao YangDepartment of Hematology, Peking University People's Hospital, Beijing, China.ORCID http://orcid.org/0000-0001-7261-8449
Bing XuDepartment of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China.ORCID http://orcid.org/0000-0002-7271-4438
Ying LuDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Yu-Fu LiDepartment of Hematology, Henan Cancer Hospital, Zhengzhou, China.
Ting NiuDepartment of Hematology, West China Hospital of Sichuan University, Chengdu, China.ORCID http://orcid.org/0000-0003-1580-1014
Ke-Qian ShiDepartment of Hematology, The First People's Hospital of Yunnan Province, Kunming, China.
Cai-Xia LiDepartment of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhen-Qian HuangDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Hong LiuDepartment of Hematology, Affiliated Hospital of Nantong University, Nantong, China.
Ling QinDepartment of Hematology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Shao-Jie WuDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Hong-Yu ZhangDepartment of Hematology, Peking University Shenzhen Hospital, Shenzhen, China.
Jian-Li WangTakeda (China) International Trading Co., Ltd, Shanghai, China.
Wen-Xin ZhangTakeda (China) International Trading Co., Ltd, Shanghai, China.
Wei-Li ZhaoShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhao.weili@yahoo.com.ORCID http://orcid.org/0000-0002-6834-1616

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42816478
PMCPMC13627086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.